Could the CCR5-Delta32 mutation be protective in SARS-CoV-2 infection?
Jazyk angličtina Země Česko Médium print
Typ dokumentu časopisecké články
PubMed
34913355
PubMed Central
PMC8884372
DOI
10.33549/physiolres.934725
PII: 934725
Knihovny.cz E-zdroje
- MeSH
- COVID-19 genetika imunologie mortalita virologie MeSH
- fenotyp MeSH
- frekvence genu MeSH
- genetická predispozice k nemoci MeSH
- interakce hostitele a patogenu MeSH
- lidé MeSH
- mutace * MeSH
- ochranné faktory MeSH
- prevalence MeSH
- receptory CCR5 genetika MeSH
- rizikové faktory MeSH
- SARS-CoV-2 imunologie patogenita MeSH
- stupeň závažnosti nemoci MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Evropa epidemiologie MeSH
- Názvy látek
- CCR5 protein, human MeSH Prohlížeč
- receptory CCR5 MeSH
Increasing evidence points to host genetics as a factor in COVID-19 prevalence and outcome. CCR5 is a receptor for proinflammatory chemokines that are involved in host responses, especially to viruses. The CCR5-delta32 minor allele is an interesting variant, given the role of CCR5 in some viral infections, particularly HIV-1. Recent studies of the impact of CCR5-delta32 on COVID-19 risk and severity have yielded contradictory results. This ecologic study shows that the CCR5-delta32 allelic frequency in a European population was significantly negatively correlated with the number of COVID-19 cases (p=0.035) and deaths (p=0.006) during the second pandemic wave. These results suggest that CCR5-delta32 may be protective against SARS-CoV-2 infection, as it is against HIV infection, and could be predictive of COVID-19 risk and severity. Further studies based on samples from populations of different genetic backgrounds are needed to validate these statistically obtained findings.
Zobrazit více v PubMed
BERNAS SN, BALDAUF H, WENDLER S, HEIDENREICH F, LANGE V, HOFMANN JA, SAUTER J, SCHMIDT AH, SCHETELIG J. CCR5Δ32 mutations do not determine COVID-19 disease course. Int J Infect Dis. 2021;105:653–655. doi: 10.1016/j.ijid.2021.02.108. PubMed DOI PMC
ESMAEILZADEH A, ELAHI R. Immunobiology and immunotherapy of COVID-19: A clinically updated overview. J Cell Physiol. 2021;236:2519–2543. https://doi:10.1002/jcp.30076 . PubMed DOI PMC
EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL. [accessed 15 April 2021]. https://www.ecdc.europa.eu/en .
HUBACEK JA, DUSEK L, MAJEK O, ADAMEK V, CERVINKOVA T, DLOUHA D, PAVEL J, ADAMKOVA V. CCR5Delta32 deletion as a protective factor in Czech first-wave COVID-19 subjects. Physiol Res. 2021;70:111–115. doi: 10.33549/physiolres.934647. PubMed DOI PMC
MEHLOTRA RK. Chemokine receptor gene polymorphisms and COVID-19: Could knowledge gained from HIV/AIDS be important? Infect Genet Evol. 2020;85:104512. doi: 10.1016/j.meegid.2020.104512. PubMed DOI PMC
PACES J, STRIZOVA Z, SMRZ D, CERNY J. COVID-19 and the immune system. Physiol Res. 2020;69:379–388. doi: 10.33549/physiolres.934492. PubMed DOI PMC
PANDA AK, PADHI A, PRUSTY BAK. CCR5 Δ32 minorallele is associated with susceptibility to SARS-CoV-2 infection and death: An epidemiological investigation. Clin Chim Acta. 2020;510:60–61. doi: 10.1016/j.cca.2020.07.012. PubMed DOI PMC
PATTERSON BK, SEETHAMRAJU H, DHODY K, CORLEY MJ, KAZEMPOUR K, LALEZARI J, PANG APS, SUGAI C, MAHYARI E, FRANCISCO EB, PISE A, RODRIGUES H, WU HL, ET AL. CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14. Int J Infect Dis. 2020;103:25–32. doi: 10.1016/j.ijid.2020.10.101. PubMed DOI PMC
SAADAT M. An evidence for correlation between the glutathione S-transferase T1 (GSTT1) polymorphism and outcome of COVID-19. Clin Chim Acta. 2020;508:213–216. doi: 10.1016/j.cca.2020.05.041. PubMed DOI PMC
SEVERE COVID-19 GWAS GROUP. ELLINGHAUS D, DEGENHARDT F, BUJANDA L, BUTI M, ALBILLOS A, INVERNIZZI P, FERNÁNDEZ J, PRATI D, BASELLI G, ASSELTA R, GRIMSRUD MM, ET AL. Genomewide association study of severe Covid-19 with respiratory failure. N Engl J Med. 2020;383:1522–1534. doi: 10.1056/NEJMoa2020283. PubMed DOI PMC
SOLLOCH UV, LANG K, LANGE V, BÖHME I, SCHMIDT AH, SAUTER J. Frequencies of gene variant CCR5-Δ32 in 87 countries based on next-generation sequencing of 1.3 million individuals sampled from 3 national DKMS donor centers. Hum Immunol. 2017;78:710–717. doi: 10.1016/j.humimm.2017.10.001. PubMed DOI
STARČEVIĆ ČIZMAREVIĆ N, TOTA M, RISTIĆ S. Does the CCR5-Δ32 mutation explain the variable coronavirus-2019 pandemic statistics in Europe? Croat Med J. 2020;61:525–526. doi: 10.3325/cmj.2020.61.525. PubMed DOI PMC
WORLDOMETER. [accessed 1 February 2021]. http://www.worldometers.info/coronavirus/countries .
YAMAMOTO N, ARIUMI Y, NISHIDA N, YAMAMOTO R, BAUER G, GOJOBORI T, SHIMOTOHNO K, MIZOKAMI M. SARS-CoV-2 infections and COVID-19 mortalities strongly correlate with ACE1 I/D genotype. Gene. 2020;758:144944. doi: 10.1016/j.gene.2020.144944. PubMed DOI PMC
